Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy

Patricia M. Flynn, Bret J. Rudy, Steven D. Douglas, Janet Lathey, Stephen A. Spector, Jaime Martinez, Margarita Silio, Marvin Belzer, Lawrence Friedman, Lawrence D'Angelo, James McNamara, Janice Hodge, Michael D. Hughes, Jane C. Lindsey, M. E. Pau, L. Noroski, W. Borkowsky, T. Hastings, S. Bakshi, M. PurswaniA. Puga, D. Cruz, M. J. O'Hara, A. J. Melvin, K. M. Mohan, C. L. Samples, M. Cavallo, M. E. Belzer, D. Tucker, M. Tanney, C. Vincent, A. C. Nyquist, K. C. Clevenger, J. E. Squires, O. Ramilo, R. Yogev, D. Fonken-Cloutier, K. Wilson, K. Bojan, J. Sever, S. Nesheim, R. Dennis, S. Rana, P. Yu, A. Wiznia, M. Chin, K. Dorio, A. Kovacs, J. Homans, Donna C. Futterman, M. DeBellis, G. Stiebel, M. Acevedo, M. Gonzales, V. R. Bonagura, C. Colter, K. Knapp, S. DiScenza, R. B. van Dyke, L. Wenthold, R. M. Viani, L. Stangl, M. H. Rathore, A. Alvarez, G. B. Scott, A. Cody, C. Gamber, H. Gay, A. Palmer, R. Pass, M. Mancao

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Background. Adolescents represent the fastest growing demographic group of new human immunodeficiency virus (HIV) infections in the United States. At present, there is little information available about their response to therapy. Methods. We studied 120 adolescents infected via high-risk behaviors who began receiving highly active antiretroviral therapy (HAART), to determine their virologic and immunologic response to therapy. Results. Subjects were enrolled at 28 sites of the Pediatric Acquired Immunodeficiency Syndrome Clinical Trials Group. After 16-24 weeks of HAART, 59% of subjects had reproducible undetectable virus loads, according to repeat measurements (virologic success). As enumerated by flow-cytometric analysis, increases in levels of CD4 helper cells (both naive and memory) and decreases in levels of CD8 suppressor cells were observed. Partial restoration of some immunologic parameters for patients who did not achieve virologic success was also observed, but to a more limited extent than for adolescents with virologic success. Adherence to HAART was the only predictor of achieving undetectable virus loads. Conclusions. Adolescents have the capacity to improve their immunologic status with HAART. Lower than expected success in virologic control is related to lack of adherence, and efforts to improve treatment outcome must stress measures to assure adherence to medication.

Original languageEnglish (US)
Pages (from-to)271-279
Number of pages9
JournalJournal of Infectious Diseases
Volume190
Issue number2
DOIs
StatePublished - Jul 15 2004

Fingerprint

Highly Active Antiretroviral Therapy
HIV-1
Viruses
Medication Adherence
Virus Diseases
Risk-Taking
Helper-Inducer T-Lymphocytes
Acquired Immunodeficiency Syndrome
Demography
Clinical Trials
HIV
Pediatrics
Therapeutics

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Flynn, P. M., Rudy, B. J., Douglas, S. D., Lathey, J., Spector, S. A., Martinez, J., ... Mancao, M. (2004). Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy. Journal of Infectious Diseases, 190(2), 271-279. https://doi.org/10.1086/421521

Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy. / Flynn, Patricia M.; Rudy, Bret J.; Douglas, Steven D.; Lathey, Janet; Spector, Stephen A.; Martinez, Jaime; Silio, Margarita; Belzer, Marvin; Friedman, Lawrence; D'Angelo, Lawrence; McNamara, James; Hodge, Janice; Hughes, Michael D.; Lindsey, Jane C.; Pau, M. E.; Noroski, L.; Borkowsky, W.; Hastings, T.; Bakshi, S.; Purswani, M.; Puga, A.; Cruz, D.; O'Hara, M. J.; Melvin, A. J.; Mohan, K. M.; Samples, C. L.; Cavallo, M.; Belzer, M. E.; Tucker, D.; Tanney, M.; Vincent, C.; Nyquist, A. C.; Clevenger, K. C.; Squires, J. E.; Ramilo, O.; Yogev, R.; Fonken-Cloutier, D.; Wilson, K.; Bojan, K.; Sever, J.; Nesheim, S.; Dennis, R.; Rana, S.; Yu, P.; Wiznia, A.; Chin, M.; Dorio, K.; Kovacs, A.; Homans, J.; Futterman, Donna C.; DeBellis, M.; Stiebel, G.; Acevedo, M.; Gonzales, M.; Bonagura, V. R.; Colter, C.; Knapp, K.; DiScenza, S.; van Dyke, R. B.; Wenthold, L.; Viani, R. M.; Stangl, L.; Rathore, M. H.; Alvarez, A.; Scott, G. B.; Cody, A.; Gamber, C.; Gay, H.; Palmer, A.; Pass, R.; Mancao, M.

In: Journal of Infectious Diseases, Vol. 190, No. 2, 15.07.2004, p. 271-279.

Research output: Contribution to journalArticle

Flynn, PM, Rudy, BJ, Douglas, SD, Lathey, J, Spector, SA, Martinez, J, Silio, M, Belzer, M, Friedman, L, D'Angelo, L, McNamara, J, Hodge, J, Hughes, MD, Lindsey, JC, Pau, ME, Noroski, L, Borkowsky, W, Hastings, T, Bakshi, S, Purswani, M, Puga, A, Cruz, D, O'Hara, MJ, Melvin, AJ, Mohan, KM, Samples, CL, Cavallo, M, Belzer, ME, Tucker, D, Tanney, M, Vincent, C, Nyquist, AC, Clevenger, KC, Squires, JE, Ramilo, O, Yogev, R, Fonken-Cloutier, D, Wilson, K, Bojan, K, Sever, J, Nesheim, S, Dennis, R, Rana, S, Yu, P, Wiznia, A, Chin, M, Dorio, K, Kovacs, A, Homans, J, Futterman, DC, DeBellis, M, Stiebel, G, Acevedo, M, Gonzales, M, Bonagura, VR, Colter, C, Knapp, K, DiScenza, S, van Dyke, RB, Wenthold, L, Viani, RM, Stangl, L, Rathore, MH, Alvarez, A, Scott, GB, Cody, A, Gamber, C, Gay, H, Palmer, A, Pass, R & Mancao, M 2004, 'Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy', Journal of Infectious Diseases, vol. 190, no. 2, pp. 271-279. https://doi.org/10.1086/421521
Flynn, Patricia M. ; Rudy, Bret J. ; Douglas, Steven D. ; Lathey, Janet ; Spector, Stephen A. ; Martinez, Jaime ; Silio, Margarita ; Belzer, Marvin ; Friedman, Lawrence ; D'Angelo, Lawrence ; McNamara, James ; Hodge, Janice ; Hughes, Michael D. ; Lindsey, Jane C. ; Pau, M. E. ; Noroski, L. ; Borkowsky, W. ; Hastings, T. ; Bakshi, S. ; Purswani, M. ; Puga, A. ; Cruz, D. ; O'Hara, M. J. ; Melvin, A. J. ; Mohan, K. M. ; Samples, C. L. ; Cavallo, M. ; Belzer, M. E. ; Tucker, D. ; Tanney, M. ; Vincent, C. ; Nyquist, A. C. ; Clevenger, K. C. ; Squires, J. E. ; Ramilo, O. ; Yogev, R. ; Fonken-Cloutier, D. ; Wilson, K. ; Bojan, K. ; Sever, J. ; Nesheim, S. ; Dennis, R. ; Rana, S. ; Yu, P. ; Wiznia, A. ; Chin, M. ; Dorio, K. ; Kovacs, A. ; Homans, J. ; Futterman, Donna C. ; DeBellis, M. ; Stiebel, G. ; Acevedo, M. ; Gonzales, M. ; Bonagura, V. R. ; Colter, C. ; Knapp, K. ; DiScenza, S. ; van Dyke, R. B. ; Wenthold, L. ; Viani, R. M. ; Stangl, L. ; Rathore, M. H. ; Alvarez, A. ; Scott, G. B. ; Cody, A. ; Gamber, C. ; Gay, H. ; Palmer, A. ; Pass, R. ; Mancao, M. / Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy. In: Journal of Infectious Diseases. 2004 ; Vol. 190, No. 2. pp. 271-279.
@article{b562f89dd20646f585e9f9defe1c4236,
title = "Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy",
abstract = "Background. Adolescents represent the fastest growing demographic group of new human immunodeficiency virus (HIV) infections in the United States. At present, there is little information available about their response to therapy. Methods. We studied 120 adolescents infected via high-risk behaviors who began receiving highly active antiretroviral therapy (HAART), to determine their virologic and immunologic response to therapy. Results. Subjects were enrolled at 28 sites of the Pediatric Acquired Immunodeficiency Syndrome Clinical Trials Group. After 16-24 weeks of HAART, 59{\%} of subjects had reproducible undetectable virus loads, according to repeat measurements (virologic success). As enumerated by flow-cytometric analysis, increases in levels of CD4 helper cells (both naive and memory) and decreases in levels of CD8 suppressor cells were observed. Partial restoration of some immunologic parameters for patients who did not achieve virologic success was also observed, but to a more limited extent than for adolescents with virologic success. Adherence to HAART was the only predictor of achieving undetectable virus loads. Conclusions. Adolescents have the capacity to improve their immunologic status with HAART. Lower than expected success in virologic control is related to lack of adherence, and efforts to improve treatment outcome must stress measures to assure adherence to medication.",
author = "Flynn, {Patricia M.} and Rudy, {Bret J.} and Douglas, {Steven D.} and Janet Lathey and Spector, {Stephen A.} and Jaime Martinez and Margarita Silio and Marvin Belzer and Lawrence Friedman and Lawrence D'Angelo and James McNamara and Janice Hodge and Hughes, {Michael D.} and Lindsey, {Jane C.} and Pau, {M. E.} and L. Noroski and W. Borkowsky and T. Hastings and S. Bakshi and M. Purswani and A. Puga and D. Cruz and O'Hara, {M. J.} and Melvin, {A. J.} and Mohan, {K. M.} and Samples, {C. L.} and M. Cavallo and Belzer, {M. E.} and D. Tucker and M. Tanney and C. Vincent and Nyquist, {A. C.} and Clevenger, {K. C.} and Squires, {J. E.} and O. Ramilo and R. Yogev and D. Fonken-Cloutier and K. Wilson and K. Bojan and J. Sever and S. Nesheim and R. Dennis and S. Rana and P. Yu and A. Wiznia and M. Chin and K. Dorio and A. Kovacs and J. Homans and Futterman, {Donna C.} and M. DeBellis and G. Stiebel and M. Acevedo and M. Gonzales and Bonagura, {V. R.} and C. Colter and K. Knapp and S. DiScenza and {van Dyke}, {R. B.} and L. Wenthold and Viani, {R. M.} and L. Stangl and Rathore, {M. H.} and A. Alvarez and Scott, {G. B.} and A. Cody and C. Gamber and H. Gay and A. Palmer and R. Pass and M. Mancao",
year = "2004",
month = "7",
day = "15",
doi = "10.1086/421521",
language = "English (US)",
volume = "190",
pages = "271--279",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy

AU - Flynn, Patricia M.

AU - Rudy, Bret J.

AU - Douglas, Steven D.

AU - Lathey, Janet

AU - Spector, Stephen A.

AU - Martinez, Jaime

AU - Silio, Margarita

AU - Belzer, Marvin

AU - Friedman, Lawrence

AU - D'Angelo, Lawrence

AU - McNamara, James

AU - Hodge, Janice

AU - Hughes, Michael D.

AU - Lindsey, Jane C.

AU - Pau, M. E.

AU - Noroski, L.

AU - Borkowsky, W.

AU - Hastings, T.

AU - Bakshi, S.

AU - Purswani, M.

AU - Puga, A.

AU - Cruz, D.

AU - O'Hara, M. J.

AU - Melvin, A. J.

AU - Mohan, K. M.

AU - Samples, C. L.

AU - Cavallo, M.

AU - Belzer, M. E.

AU - Tucker, D.

AU - Tanney, M.

AU - Vincent, C.

AU - Nyquist, A. C.

AU - Clevenger, K. C.

AU - Squires, J. E.

AU - Ramilo, O.

AU - Yogev, R.

AU - Fonken-Cloutier, D.

AU - Wilson, K.

AU - Bojan, K.

AU - Sever, J.

AU - Nesheim, S.

AU - Dennis, R.

AU - Rana, S.

AU - Yu, P.

AU - Wiznia, A.

AU - Chin, M.

AU - Dorio, K.

AU - Kovacs, A.

AU - Homans, J.

AU - Futterman, Donna C.

AU - DeBellis, M.

AU - Stiebel, G.

AU - Acevedo, M.

AU - Gonzales, M.

AU - Bonagura, V. R.

AU - Colter, C.

AU - Knapp, K.

AU - DiScenza, S.

AU - van Dyke, R. B.

AU - Wenthold, L.

AU - Viani, R. M.

AU - Stangl, L.

AU - Rathore, M. H.

AU - Alvarez, A.

AU - Scott, G. B.

AU - Cody, A.

AU - Gamber, C.

AU - Gay, H.

AU - Palmer, A.

AU - Pass, R.

AU - Mancao, M.

PY - 2004/7/15

Y1 - 2004/7/15

N2 - Background. Adolescents represent the fastest growing demographic group of new human immunodeficiency virus (HIV) infections in the United States. At present, there is little information available about their response to therapy. Methods. We studied 120 adolescents infected via high-risk behaviors who began receiving highly active antiretroviral therapy (HAART), to determine their virologic and immunologic response to therapy. Results. Subjects were enrolled at 28 sites of the Pediatric Acquired Immunodeficiency Syndrome Clinical Trials Group. After 16-24 weeks of HAART, 59% of subjects had reproducible undetectable virus loads, according to repeat measurements (virologic success). As enumerated by flow-cytometric analysis, increases in levels of CD4 helper cells (both naive and memory) and decreases in levels of CD8 suppressor cells were observed. Partial restoration of some immunologic parameters for patients who did not achieve virologic success was also observed, but to a more limited extent than for adolescents with virologic success. Adherence to HAART was the only predictor of achieving undetectable virus loads. Conclusions. Adolescents have the capacity to improve their immunologic status with HAART. Lower than expected success in virologic control is related to lack of adherence, and efforts to improve treatment outcome must stress measures to assure adherence to medication.

AB - Background. Adolescents represent the fastest growing demographic group of new human immunodeficiency virus (HIV) infections in the United States. At present, there is little information available about their response to therapy. Methods. We studied 120 adolescents infected via high-risk behaviors who began receiving highly active antiretroviral therapy (HAART), to determine their virologic and immunologic response to therapy. Results. Subjects were enrolled at 28 sites of the Pediatric Acquired Immunodeficiency Syndrome Clinical Trials Group. After 16-24 weeks of HAART, 59% of subjects had reproducible undetectable virus loads, according to repeat measurements (virologic success). As enumerated by flow-cytometric analysis, increases in levels of CD4 helper cells (both naive and memory) and decreases in levels of CD8 suppressor cells were observed. Partial restoration of some immunologic parameters for patients who did not achieve virologic success was also observed, but to a more limited extent than for adolescents with virologic success. Adherence to HAART was the only predictor of achieving undetectable virus loads. Conclusions. Adolescents have the capacity to improve their immunologic status with HAART. Lower than expected success in virologic control is related to lack of adherence, and efforts to improve treatment outcome must stress measures to assure adherence to medication.

UR - http://www.scopus.com/inward/record.url?scp=3242731879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242731879&partnerID=8YFLogxK

U2 - 10.1086/421521

DO - 10.1086/421521

M3 - Article

C2 - 15216461

AN - SCOPUS:3242731879

VL - 190

SP - 271

EP - 279

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 2

ER -